Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer.
Catherine A. Foss,James Fox,Georg Feldmann,Anirban Maitra,Christine Iacobuzio-Donohue,Scott E. Kern,Ralph H. Hruban,Martin G. Pomper +7 more
TL;DR: Both anti-claudin 4 and anti-PSCA demonstrate promise as radiodiagnostic and possibly radiotherapeutic agents for human pancreatic cancers.
read more
Abstract: Global expression profiling of pancreatic cancers has identified two cell surface molecules, claudin 4 and prostate stem cell antigen (PSCA), as being overexpressed in the vast majority of cases. Two antibodies, anti-claudin 4 and anti-PSCA, were radiolabeled with iodine 125 ((125)I) for imaging pancreatic cancer xenografts in mice using gamma scintigraphy and single-photon emission computed tomography-computed tomography (SPECT-CT). Immunofluorescence staining of intact and permeabilized Colo357 human pancreatic cancer cells showed strong extracellular staining by both anti-PSCA and anti-claudin 4. Biodistribution studies in claudin 4 and PSCA-expressing Colo357 and PANC-1 subcutaneous xenograft models in mice showed that [(125)I]anti-claudin 4 tumor to muscle ratio uptake was 4.3 in Colo357 at 6 days postinjection and 6.3 in PANC-1 xenografts at 4 days postinjection. Biodistribution of [(125)I]anti-PSCA showed tumor to muscle ratio uptake of 4.9 in Colo357 at 6 days postinjection. Planar gamma scintigraphic imaging in Colo357 xenograft-bearing mice showed clear tumor uptake of [(125)I]anti-claudin 4 by 24 hours postinjection and by 48 hours postinjection for [(125)I]anti-PSCA. SPECT-CT imaging with [(125)I]anti-claudin 4 and [(125)I]anti-PSCA in an L3.6PL orthotopic xenograft model showed strong tumor and spleen uptake at 5 days postinjection. Both anti-claudin 4 and anti-PSCA demonstrate promise as radiodiagnostic and possibly radiotherapeutic agents for human pancreatic cancers.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
•Journal Article
Update on pancreatic intraepithelial neoplasia.
TL;DR: Pancreatic intraepithelial neoplasia (PanIN) is a histologically well-defined precursor to invasive ductal adenocarcinoma of the pancreas and the association of acinar-ductal metaplasia with PanIN lesions has led some to hypothesize that PanINs develop from acinar cells that undergo acinar
269
New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8
Zarir Karanjawala,Peter B. Illei,Raheela Ashfaq,Jeffrey R. Infante,Kathleen M. Murphy,Akhilesh Pandey,Richard D. Schulick,Jordan M. Winter,Rajni Sharma,Anirban Maitra,Michael Goggins,Ralph H. Hruban +11 more
TL;DR: Claudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductalAdenocARCinomas.
Molecular Imaging of Pancreatic Cancer with Antibodies
TL;DR: This review discusses recent advances in molecular imaging of pancreatic cancer using antibody-based imaging agents by summarizing the current progress in each type of molecular imaging modality.
70
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities
Savita Bisht,Georg Feldmann,Jan Bart M. Koorstra,Jan Bart M. Koorstra,Michael Mullendore,Hector A Alvarez,Collins Karikari,Michelle A. Rudek,Carlton K. K. Lee,Amarnath Maitra,Anirban Maitra +10 more
TL;DR: NMA622 nanoparticles provide a suitable platform for oral delivery of water-insoluble drugs like rapamycin for cancer therapy, and show favorable in vivo pharmacokinetics and therapeutic efficacy in a xenograft model of human pancreatic cancer.
68
Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.
Georg Feldmann,Anirban Maitra +1 more
TL;DR: A review of recent literature on the molecular genetics of pancreatic cancer is presented and clinical implications for the development of novel diagnostic and therapeutic approaches are emphasized.
63
References
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
20.2K
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.
Zhennan Gu,George Thomas,Joyce Yamashiro,Shintaku Ip,Frederick J. Dorey,Arthur B. Raitano,Owen N. Witte,Jonathan W. Said,Massimo Loda,Robert E. Reiter +9 more
TL;DR: Examination of PSCA protein expression in clinical specimens of human prostate cancer found it to be a useful molecular target in advanced prostate cancer and may have prognostic utility.
472
•Journal Article
Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs
Dik J. Kwekkeboom,Jan Mueller-Brand,Giovanni Paganelli,Lowell Anthony,Stanislas Pauwels,Larry K. Kvols,Thomas M. O'Dorisio,Roelf Valkema,Lisa Bodei,Marco Chinol,Helmut R. Maecke,Eric P. Krenning +11 more
TL;DR: Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors, and results obtained with [(90)Y-DOTA(0),Tyr(3)]octreotide and [(177)Lu-Dota(0,Tyr (3)] octreotate are very encouraging in terms of tumor regression.
394
Design and application of diabodies, triabodies and tetrabodies for cancer targeting
Aneta Todorovska,R C Roovers,Olan Dolezal,Alexander A. Kortt,Hennie R. Hoogenboom,Peter J. Hudson +5 more
TL;DR: This review describes the design and expression of diabodies, triabodies and tetrabodies using examples of scFv molecules that target viruses and cancer and highlights a number of cancer-targeting scFV multimers that have recently successfully undergone pre-clinical trials for in vivo stability and efficacy.
371
Related Papers (5)
Sunil R. Hingorani,Emanuel F. Petricoin,Anirban Maitra,Vinodh N. Rajapakse,Catrina King,Michael A. Jacobetz,Sally Ross,Thomas P. Conrads,Timothy D. Veenstra,Ben A. Hitt,Yoshiya Kawaguchi,Donald J. Johann,Lance A. Liotta,Howard C. Crawford,Mary E. Putt,Tyler Jacks,Christopher V.E. Wright,Ralph H. Hruban,Andrew M. Lowy,David A. Tuveson +19 more
[...]
Preston Spencer,John L. Cameron,Lin +2 more
- 05 May 2000